Clinical Development

Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

by
Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibodies and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, payload … Read more

Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

by
Clinical Development Strategies for Antibody-Drug Conjugates (ADCs)

Due to the differences in selecting target antigens, effective payloads, linkers, and conjugation methods for antibody-drug conjugates (ADCs), there is structural diversity and complexity. Moreover, ADCs cannot simply be equated to a combination of antibody drugs and effective payloads, as there are numerous challenges in clinical development, including the complexity of pharmacokinetics, insufficient tumor targeting, … Read more

Training Recommendation | Analysis of ADC Clinical Development Path and Registration Strategies

by

Organizer China Chemical Enterprise Management Association Pharmaceutical Chemical Committee Yaocheng Material Information Technology (Beijing) Co., Ltd. Relevant Units Antibody-drug conjugates (ADCs) have become a major focus in pharmaceutical research and development in recent years. As of the end of 2023, 15 ADC drugs have been approved for marketing worldwide, and over 900 ADC drugs are … Read more

Clinical Development of ADCs for Solid Tumors: 40 Years of Progress

by
Clinical Development of ADCs for Solid Tumors: 40 Years of Progress

Clinical Development of ADCs for Solid Tumors The currently approved ADCs for solid tumors are listed in the table below: ADCs Target Indications T-DM1 HER2 HER2-positive metastatic breast cancer SG (sacituzumab govitecan) Trop2 Triple-negative breast cancer (TNBC) Metastatic urothelial carcinoma (mUC) sacituzumab tirumotecan Trop2 TNBC, NSCLC Gastric cancer/gastroesophageal junction cancer, mUC enfortumab vedotin Nectin-4 Locally … Read more